Form 4: Arteris Inc. Insider Trades: VP Sells Shares

Arteris, Inc. VP and General Counsel Paul L. Alpern reported transactions involving the sale of common stock and the acquisition of stock options on July 1, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• Paul L. Alpern, VP and General Counsel of Arteris, Inc., executed a series of stock transactions on July 1, 2026.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on February 23, 2026.
• Alpern acquired 4,000 incentive stock options at $0.56 per share and 2,500 non-qualified stock options at $9.28 per share.
• Concurrently, Alpern sold a total of 4,419 shares of common stock at weighted average prices ranging from $43.70 to $47.50.
• Following these transactions, Alpern beneficially owns 80,384 shares of common stock directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant sale of shares by a key executive, despite the use of a 10b5-1 plan.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially less market-sensitive trading activity.
• Alpern acquired both incentive and non-qualified stock options, suggesting continued engagement with the company's equity incentive structure.

Negatives

• A significant number of shares were sold by a key executive, which could be interpreted negatively by the market.
• The sales occurred at prices significantly higher than the exercise prices of the acquired options.

Risks

• Potential for negative market perception due to insider selling, even if conducted under a pre-arranged plan.
• The weighted average sale prices indicate a range of selling prices, with some sales occurring at the higher end of the range.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The transactions were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026.
• The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.70 to $44.69 inclusive.
• The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The execution of a 10b5-1 plan by an executive like Paul L. Alpern is a common practice to manage personal stock sales in a way that can mitigate concerns about insider trading.

Stakeholder Impact

• Shareholders may view the executive's stock sales with caution, potentially impacting short-term stock price sentiment.
• Employees with stock options may be influenced by the executive's acquisition of new options.

Next Steps

• Continued monitoring of insider trading activity for Arteris, Inc.

Key Dates

Recommendation

The filing reports routine insider transactions under a pre-established plan. While the sale of shares by a VP could be a minor negative signal, the acquisition of options and the structured nature of the sales under a 10b5-1 plan suggest it's not a strong indicator of company performance or future outlook. Therefore, a 'hold' recommendation is appropriate pending further fundamental analysis.

Keywords

Form 4, SEC Filing, Arteris Inc., Insider Trading, Stock Options, Common Stock, 10b5-1 Plan, Paul L. Alpern, Beneficial Ownership, Securities Exchange Act